123 related articles for article (PubMed ID: 38189168)
1. Rational design of peptide inhibitors targeting HSP90-CDC37 protein-protein interaction.
Zhang Q; Yan L; Zhang Y; Zhang L; Yu J; You Q; Wang L
Future Med Chem; 2024 Jan; 16(2):125-138. PubMed ID: 38189168
[No Abstract] [Full Text] [Related]
2. Design, synthesis and bioevaluation of inhibitors targeting HSP90-CDC37 protein-protein interaction based on a hydrophobic core.
Zhang Q; Wu X; Zhou J; Zhang L; Xu X; Zhang L; You Q; Wang L
Eur J Med Chem; 2021 Jan; 210():112959. PubMed ID: 33109397
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer.
Wang L; Zhang L; Li L; Jiang J; Zheng Z; Shang J; Wang C; Chen W; Bao Q; Xu X; Jiang Z; Zhang J; You Q
Sci Adv; 2019 Sep; 5(9):eaax2277. PubMed ID: 31555737
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer.
Wang L; Jiang J; Zhang L; Zhang Q; Zhou J; Li L; Xu X; You Q
J Med Chem; 2020 Feb; 63(3):1281-1297. PubMed ID: 31935086
[TBL] [Abstract][Full Text] [Related]
5. Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
Wang L; Li L; Zhou ZH; Jiang ZY; You QD; Xu XL
Eur J Med Chem; 2017 Aug; 136():63-73. PubMed ID: 28482218
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
Li N; Xu M; Wang B; Shi Z; Zhao Z; Tang Y; Wang X; Sun J; Chen L
J Med Chem; 2019 Dec; 62(23):10798-10815. PubMed ID: 31725288
[TBL] [Abstract][Full Text] [Related]
7. Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function.
Wang L; Li L; Gu K; Xu XL; Sun Y; You QD
Curr Drug Targets; 2017; 18(13):1572-1585. PubMed ID: 27231111
[TBL] [Abstract][Full Text] [Related]
8. Medium-Throughput Detection of Hsp90/Cdc37 Protein-Protein Interaction Inhibitors Using a Split
Siddiqui FA; Parkkola H; Manoharan GB; Abankwa D
SLAS Discov; 2020 Feb; 25(2):195-206. PubMed ID: 31662027
[TBL] [Abstract][Full Text] [Related]
9. Optimization and bioevaluation of Cdc37-derived peptides: An insight into Hsp90-Cdc37 protein-protein interaction modulators.
Wang L; Li L; Fu WT; Jiang ZY; You QD; Xu XL
Bioorg Med Chem; 2017 Jan; 25(1):233-240. PubMed ID: 27818030
[TBL] [Abstract][Full Text] [Related]
10. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning.
Smith JR; Workman P
Cell Cycle; 2009 Feb; 8(3):362-72. PubMed ID: 19177013
[TBL] [Abstract][Full Text] [Related]
11. Cdc37 (cell division cycle 37) restricts Hsp90 (heat shock protein 90) motility by interaction with N-terminal and middle domain binding sites.
Eckl JM; Rutz DA; Haslbeck V; Zierer BK; Reinstein J; Richter K
J Biol Chem; 2013 May; 288(22):16032-42. PubMed ID: 23569206
[TBL] [Abstract][Full Text] [Related]
12. The Therapeutic Potential of Targeting Hsp90-Cdc37 Interactions in Several Diseases.
Zhang X; Li S; Li Z; Cheng L; Liu Z; Wang C
Curr Drug Targets; 2022; 23(10):1023-1038. PubMed ID: 35400341
[TBL] [Abstract][Full Text] [Related]
13. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells.
Zhang T; Hamza A; Cao X; Wang B; Yu S; Zhan CG; Sun D
Mol Cancer Ther; 2008 Jan; 7(1):162-70. PubMed ID: 18202019
[TBL] [Abstract][Full Text] [Related]
14. Targeting the HSP90-CDC37-kinase chaperone cycle: A promising therapeutic strategy for cancer.
Wang L; Zhang Q; You Q
Med Res Rev; 2022 Jan; 42(1):156-182. PubMed ID: 33846988
[TBL] [Abstract][Full Text] [Related]
15. Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology.
Lerner Y; Sukumaran S; Chua MS; So SK; Qvit N
J Vis Exp; 2022 Mar; (181):. PubMed ID: 35435890
[TBL] [Abstract][Full Text] [Related]
16. Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions.
Jiang Y; Bernard D; Yu Y; Xie Y; Zhang T; Li Y; Burnett JP; Fu X; Wang S; Sun D
J Biol Chem; 2010 Jul; 285(27):21023-36. PubMed ID: 20413594
[TBL] [Abstract][Full Text] [Related]
17. Design of Disruptors of the Hsp90-Cdc37 Interface.
D'Annessa I; Hurwitz N; Pirota V; Beretta GL; Tinelli S; Woodford M; Freccero M; Mollapour M; Zaffaroni N; Wolfson H; Colombo G
Molecules; 2020 Jan; 25(2):. PubMed ID: 31952296
[TBL] [Abstract][Full Text] [Related]
18. Hsp90·Cdc37 Complexes with Protein Kinases Form Cooperatively with Multiple Distinct Interaction Sites.
Eckl JM; Scherr MJ; Freiburger L; Daake MA; Sattler M; Richter K
J Biol Chem; 2015 Dec; 290(52):30843-54. PubMed ID: 26511315
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification.
Li L; Chen N; Xia D; Xu S; Dai W; Tong Y; Wang L; Jiang Z; You Q; Xu X
Cell Chem Biol; 2021 Oct; 28(10):1446-1459.e6. PubMed ID: 33932325
[TBL] [Abstract][Full Text] [Related]
20. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S30. PubMed ID: 21342561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]